“Normalized miR-148a-3p as Biomarker for Predicting Trastuzumab-Based Therapy Response in Advanced HER2-Positive Esophago-Gastric Cancer Patients: A Study”

https://pubmed.ncbi.nlm.nih.gov/38094609

This study suggests that normalized miR-148a-3p may be a relevant biomarker for predicting the response to trastuzumab-based therapy in advanced HER2-positive esophago-gastric cancer patients.